^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PIK3CD expression

i
Other names: PIK3CD, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta, Phosphatidylinositol 4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform, PtdIns-3-Kinase Subunit P110-Delta, Phosphoinositide-3-Kinase C, PI3Kdelta, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta Short Variant 8/20, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta Short Variant 20, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Short Variant
Entrez ID:
Related biomarkers:
10h
JAK3/STAT5 signaling-triggered upregulation of PIK3CD contributes to gastric carcinoma development. (PubMed, J Cell Commun Signal)
These observations may setup a new crosstalk between tumor inflammatory microenvironment, IL2/JAK3/STAT5 signaling and PI3K/AKT signaling. Targeting PIK3CD may be a promising therapy strategy for GC.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • JAK3 (Janus Kinase 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
PIK3CD expression
4ms
Comparative Transcriptome Analyses in Mantle Cell Lymphoma (MCL): Evidence of E2F1 As a Major Target in Aggressive Blastoid MCL Model (ASH 2023)
The mainstay of MCL therapies remains the chemo-immunotherapy followed by autologous transplantation but recently several novel therapies have been developed such as BTK inhibitors, Venetoclax, CDK4/6 inhibitors and more recently CAR-T therapies...Finally, the expression of PIK3CD which encodes for a therapeutic target in MCL (such as PI3KDelta inhibitor Idelalisib) was also significantly repressed in UPN-1 as compared to nine other MCL cell lines...This cell line exhibited a major upregulation of E2F1 expression and a down regulation of the cell cycle inhibitor CDKN1A(p21). The potential effects of the direct inhibition of E2F1 using the targeted inhibitor MTA demonstrated a reduction in cell proliferation and induction of apoptosis, suggesting the possibility of associating clinically acceptable E2F1 inhibition strategies to other current therapies.
BRCA Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • RAD51 (RAD51 Homolog A) • CDK2 (Cyclin-dependent kinase 2) • CCNB2 (Cyclin B2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKBIA (NFKB Inhibitor Alpha 2) • E2F1 (E2F transcription factor 1)
|
TP53 mutation • PIK3CD expression • NFKB1 expression
|
Venclexta (venetoclax) • Zydelig (idelalisib)
5ms
Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies (ASH 2023)
To further validate this finding, the combination of roginolisib with venetoclax or with another bcl-2 inhibitor S55746 was tested in a broad range of lymphoma cell lines including GRANTA519, JVM2, SP49 (MCL); FARAGE, TMD8 (diffuse large B cell lymphoma); MEC1 (chronic lymphocytic leukemia); MJ (cutaneous T cell lymphoma); and YT (NK lymphoma)...Other BCRi such as idelalisib, duvelisib and acalabrutinib were used at 5 μM concentrations as positive controls...In addition, roginolisib synergized with venetoclax in lymphoma cell lines and CLL patient samples. Our data support extending this combination strategy to clinical trials in hematological malignancies.
IO biomarker
|
MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
BCL2 expression • PIK3CD expression
|
Venclexta (venetoclax) • Calquence (acalabrutinib) • Zydelig (idelalisib) • Copiktra (duvelisib) • S55746 • roginolisib (IOA-244)
5ms
PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma. (PubMed, Discov Oncol)
Our findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.
Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MIR30B (MicroRNA 30b) • COL6A3 (Collagen Type VI Alpha 3 Chain) • GLI2 (GLI Family Zinc Finger 2) • PRRX1 (Paired Related Homeobox 1) • LAMB1 (Laminin Subunit Beta 1) • RAB32 (RAB32, Member RAS Oncogene Family)
|
PIK3CD expression
7ms
Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers. (PubMed, Front Endocrinol (Lausanne))
In-vitro functional assays have further demonstrated that a combination of Idelalisib and SRPIN340 achieved a synergistic drug effect (with drastically reduced cell viabilities/growths of tumor spheroids) in inhibiting the advanced tumor cells. In summary, our study has suggested a promising potential of utilizing PI3Kδ-S (an oncogenic isoform conferring drug resistance and exempt from PTEN regulation) as a prognostic biomarker and drug target in advanced endocrine cancers.
Journal
|
PTEN (Phosphatase and tensin homolog) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • SRPK1 (SRSF Protein Kinase 1)
|
PTEN expression • PIK3CD expression • PTEN overexpression • PTEN negative
|
Zydelig (idelalisib)
10ms
Patient derived tumor cells identify mechanistically rational combinations for the PI3Kdelta inhibitor roginolisib in solid and haematologic malignancies. (EACR 2023)
Material and MethodsWe have used patient derived tumor cells to evaluate roginolisib in combination with immune-targeted or molecularly-targeted therapies to identify synergies that could be translated to future clinical studies.Results and DiscussionsHere, we show that in two ex vivo co-culture models of patient-derived mesothelioma cells with matched PBMC, the addition of roginolisib to cisplatin plus nivolumab specifically increased activated Ki67+/IFNg+ CD8 T cells and M1-like macrophages, and concomitantly decreased Tregs, exhausted TIM3+ CD8 T cells and MDSCs with an overall effect to increase the antitumoral immune response. Our data supports combining roginolisib with checkpoint inhibitors, for example in lung cancers, and targeted molecular therapies such as BCL2 inhibitors in CLL. The mechanistic synergy of these combinations has potential to provide greater patient benefit compared to the use of these medicines as single agents.
Clinical • PD(L)-1 Biomarker • IO biomarker • Tumor cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
|
Opdivo (nivolumab) • cisplatin • roginolisib (IOA-244)
11ms
SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA (EHA 2023)
Our data demonstrated for the first time the synergistic effect of a novel combination of KPT-330 and CX-4945 on cell growth arrest and apoptosis in AML cells, and identify the underlying mechanism bytargeting the PIK3CD/AKT1/FOXO3 signaling pathway, which highlighted the feasibility of clinical trials for combination therapy of AML patients.
IO biomarker
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • ANXA5 (Annexin A5)
|
PIK3CD expression • PIK3CD overexpression
|
Xpovio (selinexor) • silmitasertib (CX-4945)
12ms
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. (PubMed, Cancer Res Commun)
IOA-244 is a first-in-class non-ATP-competitive, PI3Kδ inhibitor with direct antitumor in vitro activity correlated with PI3Kδ expression. The ability to modulate T cells, in vivo antitumor activity in various models with limited toxicity in animal studies provides the rationale for the ongoing trials in patients with solid tumors and hematologic cancers.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PIK3CD expression
|
roginolisib (IOA-244)
1year
Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant PIK3CD Splice Variant in African American Prostate Cancer. (PubMed, Cancers (Basel))
Compared with PCa expressing the full-length PI3Kδ-L, PCa expressing PI3Kδ-S exhibits enhanced drug resistance properties, including a higher cell viability, more antiapoptotic and invasive capacities, and constitutively activated PI3K/AKT signaling, in the presence of PI3Kδ/PI3K inhibitors (Idelalisib, Seletalisib, Wortmannin, and Dactolisib). Additionally, SRSF2 has been identified as a critical splicing factor mediating exon 20 skipping in PIK3CD pre-mRNA. The inhibition of the SRSF2 activity by SRPIN340 successfully sensitizes AA PCa cells to PI3Kδ inhibitors, suggesting a novel therapeutic option for Idelalisib-resistant tumors.
Journal
|
SRSF2 (Serine and arginine rich splicing factor 2) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
|
dactolisib (RTB101) • Zydelig (idelalisib)
1year
Oncogenic potential of PIK3CD in glioblastoma is exerted through cytoskeletal proteins PAK3 and PLEK2. (PubMed, Lab Invest)
Mechanistically, PIK3CD regulates the activity of p21 activated kinase (PPAK3) and plecstrin 2 (PLEK2) through axonogenesis pathway. The findings provide a novel mechanism of PIK3CD-mediated GBM development and suggest PIK3CD might be a target of GBM.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PLEK2 (Pleckstrin 2)
|
PIK3CD expression
3years
[VIRTUAL] PI3Kγδ inhibitor combined with radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer model and humanized patient-derived xenograft model (AACR 2021)
A PD-1 blockade (10 mg/kg) and a PI3Kγδ inhibitor (IPI145; 15 mg/kg) were then administered every other day for 2 weeks... These findings collectively indicate that PI3Kγ and PI3Kδ are clinically relevant targets in an immunosuppressive TME. Combining PI3Kγδ inhibitor, RT, and PD-1 blockade may thus be a viable approach, helping to overcome the therapeutic resistance of immunologically cold tumors such as breast cancer.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
|
Copiktra (duvelisib)
over3years
Mechanism of MiR-224 Affecting DLBCL Cell Proliferation and Invasion by Targeted Inhibition of PIK3CD (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
MiR-224 plays a key role in the progression of DLBCL, and the proliferation and invasion of HBL1 cells can be suppressed by targeted inhibition of PIK3CD.
Journal
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
over3years
CiRS-7 functions as a ceRNA of RAF-1/PIK3CD to promote metastatic progression of oral squamous cell carcinoma via MAPK/AKT signaling pathways. (PubMed, Exp Cell Res)
Our results suggested that ciRS-7 can interact directly with miR-7, resulting in upregulation of RAF-1/PIK3CD expression and enhancing metastatic progression of OSCC.
Journal
|
RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MIR7 (MicroRNA 7)
|
PIK3CD expression
over3years
Molecular mechanism of gossypol mediating CCL2 and IL‑8 attenuation in triple‑negative breast cancer cells. (PubMed, Mol Med Rep)
Additionally, in MM‑468 cells, the compound downregulated the release of IL‑8 through repressing IL‑8, MAPK1, MAPK3, CCDC88A, STAT3 and PIK3CD gene expression. In conclusion, the data obtained in the present study indicate that the polyphenol compound GOSS may provide a valuable tool in TNBC therapy.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MAPK1 (Mitogen-activated protein kinase 1) • CCL2 (Chemokine (C-C motif) ligand 2) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
|
PIK3CD expression • CXCL8 expression
almost4years
Long noncoding RNA DLEU2 predicts a poor prognosis and enhances malignant properties in laryngeal squamous cell carcinoma through the miR-30c-5p/PIK3CD/Akt axis. (PubMed, Cell Death Dis)
In conclusion, we found that the novel LSCC-related gene DLEU2 enhances the malignant properties of LSCCs via the miR-30c-5p/PIK3CD/Akt axis. DLEU2 and its targeted miR-30c-5p/PIK3CD/Akt axis may represent valuable prognostic biomarkers and therapeutic targets for LSCCs.
Journal
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
almost4years
Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. (PubMed, PeerJ)
Furthermore, TCPA prognostic analysis observed that several of the key molecules of the PI3K/AKT/mTOR signaling pathway &lsqb;PTEN, p-AKT (S473) and p-mTOR (S2448)] were also positively correlated with OS in patients with ccRCC (P < 0.05). In conclusion, the present study suggested that several members of the PI3K/AKT/mTOR signaling pathway, especially PTEN, may be favorable prognostic factors in ccRCC, which indicated that the PI3K/AKT/mTOR signaling pathway may be implicated in ccRCC initiation and progression.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
|
PIK3CD expression
almost4years
[VIRTUAL] Single cell expression analysis of PIK3 genes to direct solid tumor treatment with the dual PI3K-δ,γ inhibitor duvelisib (AACR-II 2020)
These results indicate that PI3Kδ expression is observed in both the immune cells which are fashioning the suppressive microenvironment and in cancer cells. These findings suggest an approach to identify patients for treatment guided by cell type expression of PI3K isoforms, and provide strategies for duvelisib use as monotherapy and in combinations with PD-1 checkpoint inhibitors and other agents.
BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
|
PIK3CD expression • PIK3CG expression
|
Copiktra (duvelisib)
almost4years
[VIRTUAL] The dual PI3K-δ/PI3K-γ inhibitor duvelisib inhibits signaling and proliferation of solid tumor cells expressing PI3K-δ and/or PI3K-γ (AACR-II 2020)
Taken together, these findings indicate that in addition to the established effects of duvelisib on malignant B cells and non-malignant immune cells of the TME, duvelisib can also directly inhibit signaling and proliferation of solid tumor cells expressing PI3K-δ and/or PI3K-γ, providing further rationale for clinical investigation of duvelisib for the treatment of solid tumors. Accordingly, the combination of duvelisib with pembrolizumab is currently being evaluated in patients with head and neck squamous cell carcinoma.
PD(L)-1 Biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
PIK3CD expression
|
Keytruda (pembrolizumab) • Copiktra (duvelisib)